Chemistry:Nezavist
Nezavist, also known as DCUK-OEt, is a peripherally selective GABAA receptor positive allosteric modulator which is under development for the treatment of alcoholism and depressive disorders.[1][2][3][4] It is taken orally.[1] The drug is a positive allosteric modulator (PAM) specifically of the etomidate allosteric site of the GABAA receptor.[4] As it does not cross the blood–brain barrier, Nezavist is peripherally selective and does not directly produce central nervous system effects.[3] Nonetheless, the drug has been found to reduce alcohol self-administration in rodents, perhaps via intestinal stimulation of the vagus nerve.[4] Nezavist is under development by Lohocla Research.[1][2] As of October 2025, it is in phase 1 clinical trials for alcoholism and the preclinical research stage of development for depressive disorders.[1][2]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "DCUK OEt". 10 October 2025. https://adisinsight.springer.com/drugs/800048178.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Nezavist with Synapse". 8 May 2025. https://synapse.patsnap.com/drug/cdb8df9d18c04b68a594120a24f20a27.
- ↑ 3.0 3.1 "Engaging Gut-to-Brain Signalling to Treat Alcohol Use Disorder". Addiction Biology 31 (3). March 2026. doi:10.1111/adb.70144. PMID 41879717.
- ↑ 4.0 4.1 4.2 "Nezavist (DCUK-OEt) and aminoquinoline analogues interact with the etomidate site and display a complex mode of modulatory action of the GABAA receptor". European Journal of Pharmacology 1012. January 2026. doi:10.1016/j.ejphar.2025.178464. PMID 41419089.
 |  |
